Encapsulation in lipid-core nanocapsules improves topical treatment with the potent antileishmanial compound CH8

Cutaneous leishmaniasis (CL) is a neglected parasitic disease conventionally treated by multiple injections with systemically toxic drugs. Aiming at a more acceptable therapy, we developed lipid-core nanocapsules (LNCs) entrapping the potent antileishmanial chalcone (CH8) for topical application. Rh...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine 2020-02, Vol.24, p.102121-102121, Article 102121
Main Authors: Escrivani, Douglas O, Lopes, Milene Valéria, Poletto, Fernanda, Ferrarini, Stela Regina, Sousa-Batista, Ariane J., Steel, Patrick G., Guterres, Sílvia Stanisçuaski, Pohlmann, Adriana Raffin, Rossi-Bergmann, Bartira
Format: Article
Language:English
Subjects:
Drug delivery
Leishmaniasis
Lipid-core nanocapsules
Nitrochalcone
Skin
Topical treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous leishmaniasis (CL) is a neglected parasitic disease conventionally treated by multiple injections with systemically toxic drugs. Aiming at a more acceptable therapy, we developed lipid-core nanocapsules (LNCs) entrapping the potent antileishmanial chalcone (CH8) for topical application. Rhodamine-labeled LNC (Rho-LNC-CH8) was produced for imaging studies. LNC-CH8 and Rho-LNC-CH8 had narrow size distributions (polydispersity index
ISSN:1549-9634
1549-9642
DOI:10.1016/j.nano.2019.102121